PRLD

Prelude Therapeutics Inc

Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001678660 Biotech & Drug Discovery

$3.88 +0.18 (+4.86%)

Oct 27 4:00 PM ET · prev $3.70

Market cap

$289.7M

Micro cap

Consensus

Buy

91% Buy or better · 11 analysts

Median target

$10.00

+158% · range $6.00–12.00

Next earnings

Nov 10

in 14 days · EPS est. −$0.14

1 year

+151.9%

from $1.54 · Oct 28

30 days

−0.8%

from $3.91

52-week range

$1.19–6.63

−41% from high · low Nov 7

Avg volume 20D

489.2K

Oct 19 spike 1.59M

Short interest

🔒 Subscribers only

Insider net

+$35.0M

3 buyers · 0 sellers · 12 mo

New fund stakes

Q2 2026 13F · 0 exits

Filing reports

analyzed by SecBot

SecBot read BULLISH 5 reports · 90 days

Balance 0 bearish · 3 bullish · 2 neutral oldest → newest, height = score

Avg score

·High conf. 4/5 ·Next Earnings date, Nov 10, 2026

Strongest BULLISH Prelude Therapeutics announced FDA clearance of its IND for PRT13722, a first-in-class oral KAT6A selective…

All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

E Apr 20 FDA: Prelude Therapeutics Presents Preclinical Data from Develo…
B Apr 21 3 insiders buy $35.0M at $4.44
R Apr 21 Three major insiders (OrbiMed Advisors, Baker Bros. Advisors, and Da…
R May 12 Prelude Therapeutics reported Q1 2026 results with a net loss of $0.…
R May 12 Prelude Therapeutics reported Q1 2026 EPS of -$0.13, beating consens…
R Sep 10 Prelude Therapeutics announced FDA clearance of its IND for PRT13722…
A Sep 17 JP Morgan initiates
X Sep 30 Short interest jumps 26.1% to 4.58M

Signal stack

Where each data set points today.

InsidersBULLISH

3 insiders bought $35.0M at an average $4.44. No open-market sales. Price is 13% below their cost.
InstitutionsBULLISH

Q2 2026: 15 added (1 new), 5 trimmed or exited. Largest new: Ra Capital Management, $34.5M.
AnalystsBULLISH

10 of 11 rate it Buy or better. Every target is above the price.
EstimatesRISING

Current-quarter EPS estimate −$0.220 → −$0.143 over 90 days. 1 up, 0 down in 30 days.
TrendDOWNTREND

15% below its 50-day average.

Who's buying

13F· Q2 2026

new positions

exits

$34.5M

in new stakes

Fund	Move	Shares	Value
RA CAPITAL MANAGEMENT, L.P.	NEW	6,475,882	$34.5M
VANGUARD CAPITAL MANAGEMENT LLC	ADD	2,009,445	$10.7M
BlackRock, Inc.	DOUBLED	1,797,501	$9.6M
MILLENNIUM MANAGEMENT LLC	DOUBLED	844,993	$4.5M
GEODE CAPITAL MANAGEMENT, LLC	DOUBLED	841,862	$4.5M
MORGAN STANLEY	ADD	503,860	$2.7M
STATE STREET CORP	DOUBLED	428,787	$2.3M
UBS Group AG	DOUBLED	318,797	$1.7M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

11 analysts

Buy 91% rate it Buy or better

Strong Buy3Buy7Hold1Sell0Strong Sell0

12-month targets · 5 analysts

$3.88 $6.00 $10.00 $12.00

Price is below the lowest target. Median implies +158%.Targets as of Oct 27, 2026.

Recent actions

Date	Firm	Action	Rating
Sep 17, 2026	JP Morgan INITIATE	INITIATE	Overweight
Jul 29, 2026	HC Wainwright & Co. REITERATE	REITERATE	Buy
May 15, 2026	Goldman Sachs INITIATE	INITIATE	Early-Stage Biotech
May 4, 2026	D. Boral Capital INITIATE	INITIATE	Buy

Insider ledger

Form 4

$35.0M

bought · 3 insiders

sold · 0 insiders

−12.6%

vs their $4.44 cost

Date	Insider	Type	Value
Jun 9, 2026	FRIEDMAN PAUL A Director	AWARD	38,000 sh
Jun 9, 2026	Sandor Victor Director	AWARD	38,000 sh
Jun 9, 2026	Bonita David P Director	AWARD	38,000 sh
Jun 9, 2026	Dorton Katina Director	AWARD	38,000 sh
Jun 9, 2026	Babler Martin Director	AWARD	38,000 sh
Jun 9, 2026	BAKER BROS. ADVISORS LP Director	AWARD	38,000 sh
May 1, 2026	Morris Charles Q Chief Medical Officer	AWARD	$2.1M
Apr 27, 2026	RA CAPITAL MANAGEMENT, L.P. 10%+ Owner	OTHER	1,407,000 sh

Earnings setup

Estimates

Nov 10

reports in 14 days

−$0.14

EPS estimate, this quarter

+35%

estimate change, 90 days

1↑ 0↓

revisions, 30 days

Current-quarter EPS estimate

−$0.220

90d

−$0.140

60d

−$0.140

30d

−$0.149

−$0.143

Now

Period	EPS est.	Range	30D rev.	Revenue
Current Q	-$0.14	-$0.16–-$0.13	-1.9%	$29.0M
Next Q	-$0.15	-$0.18–-$0.14	-8.4%	$3.9M
Current FY	-$0.57	-$0.61–-$0.54	-4.9%	$38.9M
Next FY	-$0.58	-$0.79–-$0.11	+22.7%	$36.3M

Short side

FINRA· Oct 15, 2026

🔒 Subscribers only

shares short

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 16, 2026 Other

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nas

Sep 22, 2026 SEC

A strong institutional accumulation cluster emerged in PRLD during Q2 2026, with 14 buyers adding $27.0M in net new…

INST-CLUSTER — Impact 4/10

Sep 10, 2026 SEC

Prelude Therapeutics announced FDA clearance of its IND for PRT13722, a first-in-class oral KAT6A selective degrader…

8-K — Impact 6/10

Sep 10, 2026 Press

Prelude Therapeutics announced FDA clearance to begin a Phase 1 study of PRT13722, an oral KAT6A selective degrader…

Impact 4/10

Aug 11, 2026 SEC

Prelude Therapeutics reported Q2 2026 results with a net loss of $13.9M ($0.14/share), narrower than the $31.2M loss…

8-K — Impact 4/10

Jun 30, 2026 Inst.

RA CAPITAL MANAGEMENT, L.P. — NEW

6,475,882 shares ($34.5M)

Jun 30, 2026 Inst.

VANGUARD CAPITAL MANAGEMENT LLC — ADD

2,009,445 shares ($10.7M)

Jun 9, 2026 Insider

FRIEDMAN PAUL A was granted 38,000 shares

Director

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Upcoming

Nov 10, 2026

Earnings date

PRLD Q3 2026 Earnings Scheduled — 2026-11-10

Recent

Oct 16, 2026

Press release

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

WILMINGTON, Del., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology...

Sep 30, 2026

Short interest

Short Interest: PRLD up 26% to 4.6M shares

Settlement 2026-09-30 | Days to cover: 7.91 | ≈5.73% of shares outstanding (est.)

Sep 11, 2026

Press release

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

WILMINGTON, Del., Sept. 11, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology…

Sep 10, 2026

FDA

Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader

Phase 1 study of PRT13722 in patients with HR+ breast cancer anticipated to begin enrolling patients in the fourth quarter of 2026. Phase 1 study of…